Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux)

Moreau, P, White, D, Benboubker, L et al. (12 more authors) (2018) Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux). In: Haematologica: the hematology journal. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 31.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Dates:
  • Published: 18 April 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 06 May 2020 12:24
Last Modified: 13 May 2020 10:39
Published Version: http://www.haematologica.org/content/103/s1/1.full...
Status: Published
Publisher: Ferrata Storti Foundation
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)